FDA Shows When And How To Use, Or Not To Use, Non-Inferiority Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s eagerly awaited draft guidance on non-inferiority trials should facilitate greater, and easier, use of such trials. It even allows for the possibility of using a non-inferiority design for a single supportive pivotal trial, especially if the trial uses a definitive endpoint like an outcomes assessment.
You may also be interested in...
FDA Offers Workshop On Non-Inferiority Studies Of Antibacterial Drugs
How to set the margins in non-inferiority studies of new antibacterial drugs is the hard question the workshop will tackle.
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Sponsors should take care that drug development efficiencies gained with the advent of adaptive clinical trials aren't offset by lack of opportunity to reflect on data from one trial to the next and "design a thoughtful, complete program," FDA warns in its draft guidance for adaptive trial design
Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance
Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area